Laboratorio Farmaceutico Erfo S.p.A. (ERFO) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Laboratorio Farmaceutico Erfo S.p.A. stock €0.94, price €1.08, that is 13.0% below the price, quality 63 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
52‑month range €0.8541 – €3.04 · fair‑value band €0.7100 – €1.18 · the €1.08 price screens above the €0.9400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Laboratorio Farmaceutico Erfo S.p.A. in your weekly email
Every Wednesday you see whether Laboratorio Farmaceutico Erfo S.p.A. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Laboratorio Farmaceutico Erfo S.p.A. engages in the developing and production of food supplements in Italy. It provides therapeutic solutions for andrology, gastroenterology, gynecology, neurology, dentistry, orthopedics, and vascular therapeutic areas.
Show moreShow less
Laboratorio Farmaceutico Erfo S.p.A. was founded in 2013 and is based in Villafranca Tirrena, Italy.
Stock analysis
Laboratorio Farmaceutico Erfo S.p.A. (ERFO) currently trades at €1.08, while our model-based Fair Value estimate is €0.9400, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €1.31 per share, and 5 of the 16 models we run sit above the €1.08 price.
Bear case: the Dividend Discount group reads lowest at €0.3800, and 11 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €0.7100 (bear) to €1.18 (bull), the price of €1.08 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Laboratorio Farmaceutico Erfo S.p.A. reported revenue of €9.7M in FY2025 versus €4.8M in FY2021, a compound +19.0%/yr. Reported net income was €382K in FY2025, compounding −24.4%/yr from FY2021.
Key figures
Market cap €9.2M Micro · P/E ratio 21.6 · P/S ratio 0.85 · EPS (TTM) €0.0500 · Dividend yield 6.1% · Net margin 4.0% · Return on equity 8.7% · Return on assets (EBIT) 10.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at −13%, ERFO screens richer than that median.
Fair Value models
Bear€0.7100Fair Value €0.9400Bull€1.18
Price €1.08 · Downside -13.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0429 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+65.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.2%
Dividend (yield on the price)6.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.38% → 12%
Compare Laboratorio Farmaceutico Erfo S.p.A. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside−13.0% · Below median
Profitability
Return on equity (12 months)8.7% · Above median
Return on assets6.1% · Above median
Net margin (12 months)14.8% · Top 25%
Operating margin (12 months)15.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.7% · Below median
Dividend yield (12 months)6.1% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Laboratorio Farmaceutico Erfo S.p.A. (ERFO) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of €0.9400 versus a price of €1.08, about 13% lower (overvalued).
What is the fair value of ERFO?
Our model-based fair value for Laboratorio Farmaceutico Erfo S.p.A. is €0.9400 (as of Nov 5, 2026), built from audited fundamentals. The current price: €1.08.
What is the quality score of ERFO?
Laboratorio Farmaceutico Erfo S.p.A. has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Our model-based price target is the fair value of €0.9400 (as of Nov 5, 2026) from 16 valuation models. Cautious scenario €0.7100, optimistic scenario €1.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Laboratorio Farmaceutico Erfo S.p.A. stock forecast for 2026?
Our models put fair value at €0.9400, about 13% lower versus a price of €1.08 (overvalued). Cautious scenario €0.7100, optimistic scenario €1.18. The calculation is refreshed regularly with new filings.
What is the revenue of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Laboratorio Farmaceutico Erfo S.p.A. reported trailing-twelve-month revenue of about €9.8M (latest available figure, as of Nov 5, 2026).
Does Laboratorio Farmaceutico Erfo S.p.A. pay a dividend?
Laboratorio Farmaceutico Erfo S.p.A. currently shows a dividend yield of 6.14% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Laboratorio Farmaceutico Erfo S.p.A. has a dividend yield of 6.1%.
What is the intrinsic value of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Laboratorio Farmaceutico Erfo S.p.A. it is €0.9400 per share (as of Nov 5, 2026), against a price of €1.08. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Laboratorio Farmaceutico Erfo S.p.A. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, ERFO trades above its calculated fair value: price €1.08, fair value €0.9400, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERFO?
No. The price is what the market pays today (€1.08); the fair value is what the company's own numbers justify (€0.9400). For Laboratorio Farmaceutico Erfo S.p.A. the two are €0.1400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Laboratorio Farmaceutico Erfo S.p.A. worth?
The market values Laboratorio Farmaceutico Erfo S.p.A. at about €9.2M (market capitalisation, as of Nov 5, 2026). Per share that is €1.08; our models calculate a fair value of €0.9400 per share.
What do the bullish and bearish scenarios say about ERFO?
Our models span a range for Laboratorio Farmaceutico Erfo S.p.A.: cautious scenario €0.7100, base €0.9400, optimistic €1.18 per share (as of Nov 5, 2026, price €1.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ERFO?
Laboratorio Farmaceutico Erfo S.p.A. trades at a price-to-earnings ratio of 21.6 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.9400 is built from several models across several years. Other multiples: P/B 1.2, P/S 1.8, EV/EBITDA 9.9.
How solid is the balance sheet of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Balance-sheet figures for Laboratorio Farmaceutico Erfo S.p.A. (as of Nov 5, 2026): return on equity 8.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is ERFO from its 52-week high?
Laboratorio Farmaceutico Erfo S.p.A. trades at €1.08, about 32% below its 52-week high of €1.59 and 6% above the low of €1.02 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.9400 is for.
Which stocks are comparable to Laboratorio Farmaceutico Erfo S.p.A.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Laboratorio Farmaceutico Erfo S.p.A. stock attractive at the current price?
The data as of Nov 5, 2026: price €1.08, calculated fair value €0.9400 (−13%), Quality Score 63/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ERFO calculated?
We run Laboratorio Farmaceutico Erfo S.p.A. through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €0.9400 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Laboratorio Farmaceutico Erfo S.p.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The closing price on Nov 6, 2026 was €1.08. Our model-based fair value is €0.9400, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Laboratorio Farmaceutico Erfo S.p.A. right now?
Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Laboratorio Farmaceutico Erfo S.p.A.
How large is the market capitalisation of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The market capitalisation of Laboratorio Farmaceutico Erfo S.p.A. is €9.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The price-to-sales ratio of Laboratorio Farmaceutico Erfo S.p.A. is 0.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Earnings per share at Laboratorio Farmaceutico Erfo S.p.A. are €0.0500 (price ÷ EPS = P/E 21.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The dividend yield of Laboratorio Farmaceutico Erfo S.p.A. is 6.1% (payout 133%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The net margin of Laboratorio Farmaceutico Erfo S.p.A. is 4.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The return on equity (ROE) of Laboratorio Farmaceutico Erfo S.p.A. is 8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
On an EBIT basis the return on assets of Laboratorio Farmaceutico Erfo S.p.A. is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
The operating margin of Laboratorio Farmaceutico Erfo S.p.A. is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Revenue at Laboratorio Farmaceutico Erfo S.p.A. is growing +1.7% versus a year earlier (3y avg +27.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Laboratorio Farmaceutico Erfo S.p.A. (ERFO)?
Earnings per share at Laboratorio Farmaceutico Erfo S.p.A. are growing +4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Laboratorio Farmaceutico Erfo S.p.A. (ERFO) generate?
The free cash flow of Laboratorio Farmaceutico Erfo S.p.A. is −€1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Laboratorio Farmaceutico Erfo S.p.A. (ERFO) carry?
The net debt of Laboratorio Farmaceutico Erfo S.p.A. is €295K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Laboratorio Farmaceutico Erfo S.p.A. in the live analysis
One click puts Laboratorio Farmaceutico Erfo S.p.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026